Last reviewed · How we verify
Atropine sulfate eye drops 0.01%
Atropine is a muscarinic acetylcholine receptor antagonist that blocks parasympathetic signaling in the eye to inhibit accommodation and pupil constriction.
Atropine is a muscarinic acetylcholine receptor antagonist that blocks parasympathetic signaling in the eye to inhibit accommodation and pupil constriction. Used for Myopia control in children, Cycloplegia for refraction.
At a glance
| Generic name | Atropine sulfate eye drops 0.01% |
|---|---|
| Sponsor | Oupushifang Pharmaceutical Technology Co., Ltd. |
| Drug class | Muscarinic receptor antagonist |
| Target | Muscarinic acetylcholine receptors (M1, M3) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Atropine competitively blocks muscarinic receptors on the ciliary muscle and iris sphincter muscle, preventing acetylcholine-induced contraction. This results in cycloplegia (paralysis of accommodation) and mydriasis (pupil dilation). At the low 0.01% concentration, atropine is used primarily for myopia control by reducing accommodation-driven axial elongation in the eye.
Approved indications
- Myopia control in children
- Cycloplegia for refraction
Common side effects
- Mydriasis (pupil dilation)
- Cycloplegia (accommodation paralysis)
- Photophobia (light sensitivity)
- Blurred vision
- Ocular irritation or redness
Key clinical trials
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
- PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention (PHASE1, PHASE2)
- Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine (NA)
- Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia (PHASE4)
- The Safety and Efficacy of SYD-101 in Children With Myopia (PHASE3)
- Early-Onset Myopia Intervention Project (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: